POSTER'1'
GENETIC'INVESTIGATION'OF'APOPTOTIC'GENES'IN'FAMILIAL'CASES'OF'
LYMPHOMA'
'
Dr.!Walid!Sabri!Hamadou!
!
UR! Molecular! biology! of! leukemia! and! lymphoma,! Faculty! of! Medicine! of! Sousse,! Sousse,! Tunisia;!
Biology!Department,!Hail!university,!Hail,!Saudi!Arabia!
!
Apoptosis!has!been!widely!studied;!most!cancer!cells!are!resistant!to!apoptosis!that!lead!to!
treatment!resistance.!Understanding!these!pathways!provides!valuable!clues!to!understand!
cancer!physiopathology!and!suggests!new!potential!therapeutic!strategies!in!particularly!in!
Lymphoma!in!which!apoptosis!deregulation!have!been!reported!through!several!studies.!
We! investigate! the! four! key! genes!FAS,!FASLG,!CASP8!CASP10!that! trigger! lymphocyte!
mediated!apoptosis!by!entire!genes!sequencing!in!9!Tunisian!familial!cases!of!lymphoma!(!5!
Hodgkin’s!lymphoma!and!4!NonJHodgkin’s!lymphoma).!
We!report!11!gene!variations!from!which!2!missenses,!5!synonymous!and!4!intronic!variants.!
Among! these! variants! the!CASP8:!p.Asp302His! and! p.Lys337Lys! found! in! one! case! of!
Hodgkin’s! lymphoma! and! one! case! NonJHodgkin’s! lymphoma! respectively.! These! variants!
were!reported!in!several!cancers!forms,!they!might!probably!affect!the!gene!function.!Many!
studies! highlighted!CASP10!mutations! that! may! lead! to! loss! of! apoptotic! function! in! nonJ
Hodgkin’s!lymphoma,!in!our!analysis!all!reported!CASP10!variants!were!classified!as!benign.!
We!do!not!report!deleterious!mutations!in!the!analyzed!cases!of!lymphoma,!but!we!describe!
variants!with!potential!risk.!Enlarging!the!cohorts!and!including!other!apoptotic!genes!may!
bring! further! insight! to! establish! the! association! between! lymphoma! and! apoptosis!
deregulation.!
' '
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES